Followers | 13 |
Posts | 855 |
Boards Moderated | 0 |
Alias Born | 03/22/2022 |
Monday, October 16, 2023 2:41:35 PM
Babylon enjoying its last days .
Recent PCSA News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/29/2024 04:15:13 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/28/2024 08:49:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:13:45 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/21/2024 08:10:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:16:05 PM
- Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:15:00 PM
- Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 03/25/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/21/2024 01:15:00 PM
- Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference • GlobeNewswire Inc. • 02/14/2024 06:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:30:35 PM
- Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule • GlobeNewswire Inc. • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 11:32:03 PM
- Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering • GlobeNewswire Inc. • 02/01/2024 09:22:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 03:46:33 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/29/2024 09:15:23 PM
- Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering • GlobeNewswire Inc. • 01/26/2024 02:04:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:35:27 PM
- Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 01:00:12 PM
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM